✦ LIBER ✦

A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

✍ Scribed by Aman U. Buzdar; Stephen E. Jones; Charles L. Vogel; Janet Wolter; Paul Plourde; Alan Webster; for the Arimidex Study Group

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 114 KB
Volume: 79
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970215)79:4<730::aid-cncr10>3.0.co;2-0

No coin nor oath required. For personal study only.

✦ Synopsis

The trial was randomized, double blind for anastrozole, open label for for the Arimidex Study Group megestrol acetate, parallel group, and multicenter. Patients were randomly assigned to receive anastrozole, 1 mg (n Å 128); anastrozole, 10 mg (n Å 130); or

📜 SIMILAR VOLUMES

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace